Loading clinical trials...
Loading clinical trials...
Long-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. Placebo
Conditions
Interventions
Semapimod
Locations
26
United States
University of California, San Francisco
San Francisco, California, United States
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States
Advanced Gastroenterology Associates
Suwanee, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Long Island Clinical Research Associates
Great Neck, New York, United States
Asher Kornbluth, MD
New York, New York, United States
Start Date
December 1, 2002
Primary Completion Date
July 1, 2004
Completion Date
September 1, 2004
Last Updated
March 28, 2025
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07383844
Lead Sponsor
Ferring Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions